. Author manuscript; available in PMC: 2023 Oct 2.

Published in final edited form as: J Subst Abuse Treat. 2022 May 20;142:108806. doi: 10.1016/j.jsat.2022.108806

Table 3.

Latent classes of multimorbidity classified by individual disease indicators, n = 1387 ALIVE participants from 2015 to 2019.

	Class 1	Class 2	Class 3	Class 4
	n = 745 (54%)	n = 368 (26%)	n = 172 (12%)	n = 102 (7%)
	Low multimorbidity	Low multimorbidity including psychiatric comorbidity	Multimorbidity	Multimorbidity including psychiatric comorbidity

Arthritis	21%	31%	49%	48%
Major psychiatric disorders (bipolar & schizophrenia)	2%	100%	0%	100%
Anxiety/depression	58%	100%	61%	100%
Diabetes	7%	0%	75%	100%
Liver fibrosis	12%	14%	38%	28%
Hypertension	96%	97%	98%	100%
Obstructive airway	38%	34%	24%	29%
Renal dysfunction	16%	17%	29%	32%

Bolded are conditional prevalences that are noteworthy for that class.